| Status | Discontinued |
| Process | STA pre-2018 |
| Referral date | 01 June 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Consultees
| Manufacturers/sponsors | Bristol Myers Squibb Pharmaceuticals (abatacept) |
| Others | Cardiff LHB |
| Department of Health | |
| Doncaster PCT | |
| Welsh Assembly Government | |
| Patient/carer groups | Action for Children |
| Action for Sick Children | |
| Action on Pain | |
| Afiya Trust | |
| Arthritic Association | |
| Arthritis and Musculoskeletal Alliance (ARMA) | |
| Arthritis Care | |
| BackCare | |
| Black Health Agency | |
| British Ethnic Health Awareness Foundation (BEHAF) | |
| Children’s Society | |
| Children’s Chronic Arthritis Association | |
| Chinese National Healthy Living Centre | |
| Confederation of Indian Organisations | |
| Equalities National Council | |
| Leonard Cheshire Disability | |
| Muslim Council of Great Britain | |
| Muslim Health Network | |
| National Children’s Bureau | |
| National Parent and Carer Council | |
| National Parent Partnership Network | |
| National Rheumatoid Arthritis Society | |
| Pain Concern | |
| Pain Relief Foundation | |
| RADAR - Royal Association for Disability and Rehabilitation | |
| Skill: National Bureau for Students with Disabilities | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| WellChild | |
| Professional groups | British Health Professionals in Rheumatology |
| British Institute of Musculoskeletal Medicine | |
| British Orthopaedic Association | |
| British Pain Society | |
| British Society for Paediatric and Adolescent Rheumatology | |
| British Society for Rheumatology | |
| British Society of Rehabilitation Medicine | |
| College of Occupational Therapists | |
| Physiotherapy Pain Association | |
| Primary Care Rheumatology Society | |
| Rheumatoid Arthritis Surgical Society | |
| Royal Society of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Paediatrics & Child Health | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine – Intellectual Disabilities Forum | |
| United Kingdom Clinical Pharmacy Association |
Commentators
| Associated Guideline Groups | National Clinical Guidelines Centre for Acute and Chronic Conditions |
| Associated Public Health Groups | None |
| Comparator manufacturer(s) | Abbott Pharmaceuticals (adalimumab) |
| Generics (UK) (sulfasalazine) | |
| IVAX Pharmaceuticals (sulfasalazine) | |
| Mayne Pharma (methotrexate) | |
| Medac UK (methotrexate) | |
| Novartis Pharmaceuticals (ciclosporin) | |
| Pfizer (sulfasalazine, methotrexate) | |
| Sanofi Aventis (hydroxychloroquine, leflunomide) | |
| Schering-Plough (infliximab) | |
| Teva UK (sulfasalazine) | |
| Wockhardt UK (methotrexate) | |
| Wyeth Laboratories (etanercept) | |
| Evidence Review Group | NHS Centre for Reviews & Dissemination and Centre for Health Economics –York |
| National Institute for Health Research Health Technology Assessment Programme | |
| General | Board of Community Health Councils in Wales |
| British National Formulary | |
| Department of Health,Social Services and Public Safety for Northern Ireland | |
| Medicines and Healthcare products Regulatory Agency (MHRA) | |
| National Association of Primary Care | |
| National Public Health Service for Wales | |
| NHS Alliance | |
| NHS Confederation | |
| NHS Purchasing and Supply Agency | |
| NHS Quality Improvement Scotland | |
| Scottish Medicines Consortium | |
| Relevant research groups | Arthritis Research Campaign |
| Bone Research Society | |
| MRC Clinical Trials Unit | |
| National Institute of Health Research | |
| United Kingdom Clinical Research Network |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 7 August 2009 | The above topic was referred to NICE as part of the 17th wave referrals. The manufacturer of abatacept has informed us that they are not in a position to submit evidence in line with the current schedule for this STA because of a delay in the regulatory process. This STA is therefore suspended. |
| 7 July 2010 | The marketing authorisation for abatacept in this therapeutic area suggests limited use of this drug for a small population of those with juvenile idiopathic arthritis. Following discussions with the Department of Health, we have therefore concluded that this topic should be removed from the work programme. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance